Catalog No.
DHG01801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
N2ICD, N2ECD, NOTCH2, hN2, Neurogenic locus notch homolog protein 2, Notch 2, Neurogenic locus notch homolog protein 3, NOTCH3, Notch 3
Concentration
0.68 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q04721 & Q9UM47
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
OMP-59R5, CAS: 1359940-55-8
Clone ID
Tarextumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer., PMID:25388163
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency., PMID:25934888
Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency., PMID:28275151
Advances in antibody therapeutics targeting small-cell lung cancer., PMID:29790694
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors., PMID:30591982
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency., PMID:30670492
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer., PMID:31347292
A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer., PMID:35330078
Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency, PMID: 28275151
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency, PMID: 30670492
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer, PMID: 25388163
Advances in antibody therapeutics targeting small-cell lung cancer, PMID: 29790694
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency, PMID: 25934888
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors, PMID: 30591982
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer, PMID: 31347292
For research use only. Not for human or drug use.
